# MHB018A Treatment in Patients With Active Thyroid Eye Disease

> **NCT06989918** · PHASE3 · RECRUITING · sponsor: **Minghui Pharmaceutical (Hangzhou) Ltd** · enrollment: 108 (estimated)

## Conditions studied

- Thyroid Associated Ophthalmopathies

## Interventions

- **DRUG:** MHB018A
- **DRUG:** MHB018A placebo

## Key facts

- **NCT ID:** NCT06989918
- **Lead sponsor:** Minghui Pharmaceutical (Hangzhou) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06989918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06989918, "MHB018A Treatment in Patients With Active Thyroid Eye Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06989918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*